v3.26.1
Description of Business and Basis of Preparation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Jun. 20, 2025
Mar. 31, 2026
Dec. 31, 2025
Product Information [Line Items]      
Accumulated deficit   $ (406,443) $ (385,144)
Cash and cash equivalents and investments   $ 72,400  
Nasdaq minimum bid price notification description   The letter from Nasdaq had no immediate effect on the listing of the Company's common stock on the Nasdaq Global Market.  
Nasdaq minimum closing bid price for common stock $ 1    
Ownership rights, description   The Company owns 100% of the rights to SCY-247, as well as additional fungerp compounds in preclinical and discovery stages of development. The FDA has granted Qualified Infectious Disease Product status, Fast Track, and Orphan Drug designations for the oral formulation of SCY-247.  
Owns percentage of right   100.00%